Literature DB >> 25474359

Burkholderia species infections in patients with cystic fibrosis in British Columbia, Canada. 30 years' experience.

James E A Zlosnik1, Guohai Zhou, Rollin Brant, Deborah A Henry, Trevor J Hird, Eshwar Mahenthiralingam, Mark A Chilvers, Pearce Wilcox, David P Speert.   

Abstract

RATIONALE: We have been collecting Burkholderia species bacteria from patients with cystic fibrosis (CF) for the last 30 years. During this time, our understanding of their multispecies taxonomy and infection control has evolved substantially.
OBJECTIVES: To evaluate the long-term (30 year) epidemiology and clinical outcome of Burkholderia infection in CF, and fully define the risks associated with infection by each species.
METHODS: Isolates from Burkholderia-positive patients (n=107) were speciated and typed annually for each infected patient. Microbiological and clinical data were evaluated by thorough review of patient charts, and statistical analyses performed to define significant epidemiological factors.
MEASUREMENTS AND MAIN RESULTS: Before 1995, the majority of new Burkholderia infections were caused by epidemic clones of Burkholderia cenocepacia. After implementation of new infection control measures in 1995, Burkholderia multivorans became the most prevalent species. Survival analysis showed that patients with CF infected with B. cenocepacia had a significantly worse outcome than those with B. multivorans, and a novel finding was that, after Burkholderia infection, the prognosis for females was significantly worse than for males.
CONCLUSIONS: B. multivorans and B. cenocepacia have been the predominant Burkholderia species infecting people with CF in Vancouver. The implementation of infection control measures were successful in preventing new acquisition of epidemic strains of B. cenocepacia, leaving nonclonal B. multivorans as the most prevalent species. Historically, survival after infection with B. cenocepacia has been significantly worse than B. multivorans infection, and, of new significance, we show that females tend toward worse clinical outcomes.

Entities:  

Keywords:  Burkholderia cepacia complex; Burkholderia gladioli; cystic fibrosis; sex; survival

Mesh:

Substances:

Year:  2015        PMID: 25474359     DOI: 10.1513/AnnalsATS.201408-395OC

Source DB:  PubMed          Journal:  Ann Am Thorac Soc        ISSN: 2325-6621


  35 in total

1.  Class III Histidine Kinases: a Recently Accessorized Kinase Domain in Putative Modulators of Type IV Pilus-Based Motility.

Authors:  Ogun Adebali; Marharyta G Petukh; Alexander O Reznik; Artem V Tishkov; Amit A Upadhyay; Igor B Zhulin
Journal:  J Bacteriol       Date:  2017-08-22       Impact factor: 3.490

2.  Burkholderia cepacia complex in cystic fibrosis in the post-epidemic period: multilocus sequence typing-based approach.

Authors:  Libor Fila; Pavel Dřevínek
Journal:  Folia Microbiol (Praha)       Date:  2017-03-31       Impact factor: 2.099

3.  Crystal structures of the Burkholderia multivorans hopanoid transporter HpnN.

Authors:  Nitin Kumar; Chih-Chia Su; Tsung-Han Chou; Abhijith Radhakrishnan; Jared A Delmar; Kanagalaghatta R Rajashankar; Edward W Yu
Journal:  Proc Natl Acad Sci U S A       Date:  2017-06-05       Impact factor: 11.205

4.  Whole Genome Sequence Analysis of Burkholderia contaminans FFH2055 Strain Reveals the Presence of Putative β-Lactamases.

Authors:  José J Degrossi; Cindy Merino; Adela M Isasmendi; Lorena M Ibarra; Chelsea Collins; Nicolás E Bo; Mariana Papalia; Jennifer S Fernandez; Claudia M Hernandez; Krisztina M Papp-Wallace; Robert A Bonomo; Miryam S Vazquez; Pablo Power; María S Ramirez
Journal:  Curr Microbiol       Date:  2019-02-19       Impact factor: 2.188

5.  Burkholderia orbicola sp. nov., a novel species within the Burkholderia cepacia complex.

Authors:  Leslie-Mariana Morales-Ruíz; Mariana Rodríguez-Cisneros; Jeniffer-Chris Kerber-Díaz; Fernando-Uriel Rojas-Rojas; J Antonio Ibarra; Paulina Estrada-de Los Santos
Journal:  Arch Microbiol       Date:  2022-02-17       Impact factor: 2.552

Review 6.  Regulation of Virulence by Two-Component Systems in Pathogenic Burkholderia.

Authors:  Matthew M Schaefers
Journal:  Infect Immun       Date:  2020-06-22       Impact factor: 3.441

Review 7.  The art of persistence-the secrets to Burkholderia chronic infections.

Authors:  Eric R G Lewis; Alfredo G Torres
Journal:  Pathog Dis       Date:  2016-07-19       Impact factor: 3.166

Review 8.  Cystic Fibrosis: Microbiology and Host Response.

Authors:  Edith T Zemanick; Lucas R Hoffman
Journal:  Pediatr Clin North Am       Date:  2016-08       Impact factor: 3.278

9.  Antibiotic therapy for chronic infection with Burkholderia cepacia complex in people with cystic fibrosis.

Authors:  Freddy Frost; Matthew Shaw; Dilip Nazareth
Journal:  Cochrane Database Syst Rev       Date:  2019-06-13

10.  Improved Dynamic Range of a Rhamnose-Inducible Promoter for Gene Expression in Burkholderia spp.

Authors:  Andrew M Hogan; Kevin R Jeffers; Armando Palacios; Silvia T Cardona
Journal:  Appl Environ Microbiol       Date:  2021-08-26       Impact factor: 4.792

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.